Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 10—October 2008

Research

Prophylaxis after Exposure to Coxiella burnetii

Claire E. MoodieComments to Author , Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Table 4

Summary of threshold points by group, drug efficacy, and probability of an adverse event (best estimate/upper bound estimate)

Population Drug efficacy
96.50% 40%* 82%
Primary analysis Less virulent More virulent
General population
All cases of illness 2.1/6.3 NA 2.5/7.4 3.88/11.65 1.98/5.94
Severe illness 0.08/0.24 NA 0.09/0.28 0.58/1.75 0.05/0.14
Death
0.00/1.8
NA
0.00/2.1
0.00/28.49
0.00/0.36
High-risk population
All cases of illness 2.1/6.3 NA 2.5/7.4 3.88/11.65 1.98/5.94
Severe illness 0.03/0.09 NA 0.03/0.10 0.147/0.44 0.021/0.06
Death
0.00/0.24
NA
0.00/0.28
0.00/3.5
0.00/0.05
Pregnant women
All cases of illness 4.7/13.3 11.4/32.2 5.6/15.7 9.99/28.2 4.16/11.7
Severe illness 0.002/0.006 0.005/0.014 0.002/0.007 0.0069/0.021 0.0016/0.0047
Death 0.001/0.004 0.003/0.010 0.002/0.005 0.0053/0.0156 0.0006/0.0019

*Doxycycline was not evaluated at 40% drug efficacy. NA, not available.

Main Article

TOP